Additionally, 24-week treatment of Exenatide combined with insulin glargine significantly reduced the albuminuria in T2DM patients with DKD, which provided evidence for the application of GLP-1R agonists in DKD [238]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.